Posterior Capsular Opacification
Definition
The most common complication of cataract surgery, caused by proliferation and migration of residual lens epithelial cells onto the posterior capsule, resulting in progressive visual decline months to years after surgery.
Clinical Snapshot
Posterior capsular opacification (PCO) is the most common complication of cataract surgery, occurring in approximately 20–40% of patients within 5 years of phacoemulsification. It results from the proliferation and migration of residual lens epithelial cells (LECs) onto the posterior capsule, forming a fibrous or pearl-like opacity that progressively degrades visual quality. PCO is treated definitively and safely with Nd:YAG laser posterior capsulotomy — a brief, in-office procedure that restores vision immediately. Optometrists are frequently the first to identify PCO at routine postoperative visits and play a central role in initiating the referral for laser treatment.
Epidemiology
PCO occurs in approximately 20–40% of patients within 5 years of cataract surgery, though modern square-edge IOL designs have significantly reduced this rate compared to earlier round-edge designs. It is more common in younger patients (more metabolically active LECs), patients with uveitis, and those with certain systemic conditions (diabetes, myotonic dystrophy). The rate varies by IOL material and design — hydrophobic acrylic square-edge IOLs have the lowest PCO rates.
Pathophysiology
During phacoemulsification, the anterior lens capsule is opened (capsulorhexis) and the lens nucleus and cortex are removed, leaving the posterior capsule intact as a scaffold for IOL implantation. Residual LECs on the anterior capsule and equatorial region (the "lens bow") proliferate and migrate posteriorly onto the clear posterior capsule. Two morphological forms: (1) Fibrotic PCO — anterior subcapsular fibrosis from myofibroblastic transformation of LECs; (2) Pearl PCO (Elschnig pearls) — proliferating LECs forming bladder cells on the posterior capsule. Both forms scatter and absorb light, reducing visual quality.
Risk Factors
- Younger age (more metabolically active LECs)
- Uveitis (inflammatory stimulation of LEC proliferation)
- Diabetes mellitus
- Round-edge IOL design (square-edge IOLs create a mechanical barrier to LEC migration)
- PMMA IOL material (hydrophobic acrylic has the lowest PCO rate)
- Incomplete cortical cleanup at surgery
Clinical Presentation
Gradual, progressive visual decline months to years after initially successful cataract surgery. Glare and halos. Reduced contrast sensitivity. The patient may describe vision as "going back to how it was before surgery." Slit-lamp examination: posterior capsule opacity visible on retroillumination — fibrotic PCO appears as a wrinkled, fibrous membrane; Elschnig pearls appear as a cluster of round, translucent cells. Retroillumination is the most sensitive technique for detecting early PCO.
Diagnostic Pearls
- Retroillumination at the slit lamp is the most sensitive technique for detecting PCO — the opacity is best seen against the red reflex.
- PCO must be distinguished from other causes of visual decline after cataract surgery: CME (OCT), IOL dislocation (slit-lamp), corneal decompensation (specular microscopy), and macular disease (OCT).
- The timing of visual decline is a useful clinical clue — PCO typically develops months to years postoperatively; CME typically presents within weeks.
- Nd:YAG capsulotomy is contraindicated in the presence of active CME — treat the CME first, then reassess the need for capsulotomy.
Differential Diagnosis
- Pseudophakic CME (OCT shows petaloid macular edema — weeks to months postoperatively)
- IOL dislocation or decentration (slit-lamp — IOL edge visible in the pupil)
- Corneal decompensation (Fuchs' dystrophy decompensation — specular microscopy)
- Macular disease (AMD, ERM — OCT macula)
Evidence-Based Management
Nd:YAG laser posterior capsulotomy: the definitive treatment — a brief, painless, in-office procedure using a pulsed Nd:YAG laser to create an opening in the posterior capsule. Visual recovery is immediate. Complications are rare but include: transient IOP elevation (pre-treat with apraclonidine or brimonidine; monitor IOP 1 hour post-laser), IOL pitting (minimize energy), cystoid macular edema (rare), and retinal detachment (rare — higher risk in high myopes). Post-capsulotomy: topical NSAID or corticosteroid for 1–2 weeks to reduce inflammation.
Monitoring & Follow-Up
Slit-lamp examination with retroillumination at every postoperative visit. Document BCVA and patient-reported visual symptoms. Refer for Nd:YAG capsulotomy when PCO causes clinically significant visual impairment.
Clinical Pearls
- Nd:YAG capsulotomy is one of the most effective procedures in ophthalmology — visual recovery is immediate and the complication rate is very low.
- Pre-treat with apraclonidine or brimonidine before Nd:YAG capsulotomy and check IOP 1 hour post-laser — transient IOP elevation is the most common complication.
- Do not perform Nd:YAG capsulotomy in the presence of active CME — the laser energy can worsen macular edema.
- Square-edge hydrophobic acrylic IOLs have the lowest PCO rates — this is a relevant consideration in IOL selection counseling.
Related Therapeutics — Clinician's Companion
- Anti-inflammatory Rescue — Pred Forte® (Clinician's Companion)
- Anti-inflammatory Rescue — Lotemax SM® (Clinician's Companion)
Key References
- 1.Schaumberg DA, et al. Lens capsule opacification after cataract surgery. Arch Ophthalmol. 1998.
- 2.Findl O, et al. Interventions for preventing posterior capsule opacification. Cochrane Database Syst Rev. 2010.
This entry is an educational reference designed to support clinical reasoning and awareness. It does not constitute medical advice, establish a standard of care, or replace individualized patient assessment. Clinicians should consult current guidelines and applicable clinical resources when making patient care decisions.